Retinoids have shown promise as anti-cancer and cancer preventative agents. All-trans-N-(4-hydroxyphenyl)-retinamide (4HPR) belongs to a new group of retinoids that not only inhibit the proliferation of cancer cells but also can induce apoptosis in certain cancer cells. Because of its increased efficacy against cancer cells and its low toxicity it has been entered into a number of clinical trials. However, its mechanism of action is not known, and it had been assumed that it is not a true retinoid. Here we analyze its ability to function as an activator of nuclear retinoid receptors (RARs and RXRs). We observe that, in transactivation assays, 4HPR is a potent transactivator with RAR␥ and a moderate activator with RAR␤ but is not an activator with RAR␣ and RXR␣. Furthermore, RAR␥-selective transactivation by 4HPR is enhanced on some response elements and reduced on others when compared to natural retinoids. In contrast to transactivation, 4HPR in transrepression assays functions mostly with RAR␣, RAR␤, and RXR␣. Optimal receptor activation is seen at 4HPR concentrations at which it is a potent growth inhibitor and inducer of apoptosis. We conclude that 4HPR is a highly selective activator of retinoid receptors. We propose that this selective activation of the nuclear receptors is likely to be the basis for its specific biological activities and its favorable pharmaceutical properties.
Retinoic acid (RA) 1 and its synthetic analogs, the retinoids, exert diverse biological effects and control normal growth, fetal development, differentiation, morphogenesis, metabolism, and homeostasis (1) (2) (3) . Clinically, RA and some synthetic retinoids are known to be effective against a number of skin diseases (4) and have shown promise for the treatment and prevention of several cancers (5) . Besides their beneficial effects retinoids also induce a number of undesirable side effects, limiting their clinical applications. In addition, the natural retinoids show only limited activity against most types of cancer cells. A major goal has been to develop retinoids with a higher therapeutic index and more targeted biological activities. Although the unraveling of the molecular mechanism (6 -8) has now made it possible to define retinoids that activate selectively certain receptors and/or pathways (9 -14) , such retinoids have not yet been clinically evaluated. On the other hand, other synthetic retinoids that were found a number of years ago have entered extensive clinical evaluations, although their mechanisms of action are not understood. This is in particular the case for all-trans-N-(4-hydroxyphenyl)retinamide (4HPR or fenretinide) which has been entered into a number of clinical trials and which shows promise for the treatment and prevention of breast cancer (15) (16) (17) (18) as well as several other cancers (19, 20) . 4HPR was selected for clinical trials because of its low overall toxicity, and has been successfully used as a chemopreventive agent alone and in combination with tamoxifen in high risk breast cancer patients (21, 22) , against superficial bladder cancer (23) , and oral lichen planus and leukoplakia (24, 25) . 4HPR is also a highly effective growth inhibitor of neuroblastoma cell lines (26) , malignant hemopoietic cell lines (27) , small cell lung cancer cell lines (28) , and a variety of breast cancer cell lines (29) .
The mechanism of action of 4HPR is unknown (30) . Although 4HPR does not have a terminal carboxyl group, believed to be an essential feature for active retinoids, it has been shown to have certain biological activities that are typical for retinoids. 4HPR inhibits ODC activity induction (31) and prostaglandin synthesis and enhances the immune system (32, 33) . On the other hand, 4HPR does not induce cell differentiation as RA does, but induces programmed cell death, i.e. apoptosis (26, 27, 34, 35) , while RA usually does not effectively induce apoptosis. Thus, the mechanism of action of fenretinide on cancer cells appears to differ from that of RA. To gain insight into the molecular mechanisms that allow 4HPR to function as an apoptosis-inducing anti-cancer agent with reduced toxicity, we have analyzed its effect on the nuclear retinoid receptors.
Retinoid signal transduction is mediated by a complex network of nuclear receptor interactions which has been extensively reviewed elsewhere (6 -8) . Briefly, six retinoid receptors have been identified that fall into two classes, the RARs (␣, ␤, and ␥) and the RXRs (␣, ␤, and ␥). These receptors function as transcriptional activators that bind as RAR/RXR heterodimers or 9-cis-RA-induced RXR/RXR homodimers to specific RA response elements (RARE), usually found in the 5Ј-flanking region of responsive genes. The structure of the RARE can further modulate the heterodimer response (36) . RARs and RXRs in addition can interact with the transcription factor AP-1 and inhibit its activity. This mechanism of transrepression is important since it allows retinoids to directly interfere with cell proliferation signals mediated by the transcription factor AP-1 (reviewed in Ref. 37 ). Transactivation and transrepression by retinoids can be separated, such that certain synthetic retinoids function only as transrepressors, but not as transactivators (12) . * The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ To whom correspondence should be addressed: Sidney Kimmel Cancer Center, 11099 N. Torrey Pines Rd., Suite 250, La Jolla, California 92037. Tel.: 619-623-9608; Fax: 619-623-9628. 1 The abbreviations used are: RA, retinoic acid; RAR, retinoic acid receptor; RXR, retinoic acid X receptor; RARE, retinoic acid response element; tRA, all-trans-RA; 4HPR, all-trans-N-(4-hydroxyphenyl)retinamide; 4MPR, inert metabolite of 4HPR; TPA, 12-O-tetradecanoylphorbol-13-acetate; FCS, fetal calf serum; BrdU, bromodeoxyuridine; ELISA, enzyme-linked immunosorbent assay; DR, direct repeat.
We have investigated here the transactivation and transrepression properties of 4HPR with the different retinoid receptors. We observe that 4HPR shows anti-AP-1 activity mostly with RAR␣, RAR␤, and RXR␣ but activates transcription only via RAR␥ and RAR␤. In addition, transactivation activity in the presence of RAR␥/RXR heterodimers varies on different RAREs. Optimal receptor activation is observed at concentrations at which 4HPR shows strong antiproliferative activity and induces apoptosis in a breast cancer cell line.
We propose that the high therapeutic index of 4HPR may depend, at least in part, on the ability of 4HPR to activate only a selected portion of the broad retinoid receptor response.
MATERIALS AND METHODS
Retinoids-All-trans-RA (tRA) and TPA (12-O-tetradecanoyl-phorbol-13-acetate) were obtained from Sigma and 9-cis-RA was provided by CIRD-GALDERMA. 4HPR was synthesized according to published procedures. 10 mM stock solutions for retinoids were prepared in Me 2 SO: ethanol (1:1, v/v) (tRA and 9-cis-RA) or ethanol (4HPR and 4MPR). All retinoids were diluted in culture medium to the indicated final concentration.
Culture Conditions-The estrogen receptor-positive breast cancer cell line MCF-7 and the estrogen receptor-negative breast cancer cell line Hs578T were cultured in Dulbecco's modified Eagle's medium containing 10% fetal calf serum (FCS) (Tissue Culture Biologicals) and 10 g/ml bovine insulin. The estrogen receptor-positive cell line T47D was cultured in RPMI medium 1640 containing 10% FCS and 10 g/ml bovine insulin. HeLa and CV-1 cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% bovine calf serum and FCS, respectively. The lung cancer cell line H661 was grown in RPMI medium, and Calu-6 was grown in minimal essential medium, both supplemented with 10% FCS. All cell lines were obtained from American Type Culture Collection. Cells were cultured at 37°C in humidified atmosphere containing 6% CO 2 .
Cell Proliferation Assay-Proliferation of cancer cell lines was analyzed by direct cell counting or by using a colorimetic cell proliferation kit (Promega, Madison, WI) as described previously (44) .
Apoptosis Assay-Apoptosis was measured by using a cellular DNA fragmentation ELISA kit (Boehringer Mannheim) following the manufacturer's instructions. Briefly, the cell concentration was adjusted to 10 4 cells/ml, and 100 l were plated for each well of a microtiter plate (Falcon tissue culture grade, 96-well, flat bottom). Cells were grown in RPMI medium containing 10% FCS and 10 M BrdU overnight at 37°C in a humidified atmosphere (6% CO 2 ). After BrdU-labeling, cells were grown in the absence or presence of retinoids for 24 h. After the retinoid treatment, the cells were lysed in by adding 100 l/well incubation buffer for 30 min at room temperature. The plate was then centrifuged at 250 ϫ g for 10 min, and 10 l of supernatant were removed and analyzed by ELISA following the manufacturer's instructions.
Transient Transfection Assays-Transient transfections were carried out using a modified calcium phosphate precipitation procedure as described previously (49) .
RESULTS

4HPR
Is a RAR␥-selective Transcriptional Activator-To determine whether 4HPR is a genuine retinoid and can function as a direct activator of the nuclear retinoid receptors, we examined its ability to activate a retinoid-responsive reporter gene (TREpal-CAT) in the presence of retinoid receptors. When RAR␣, ␤, and ␥ and RXR␣ expression vectors were cotransfected with the reporter gene into CV-1 cells, essentially no activation of the reporter gene by 4HPR was observed in the presence of RAR␣ (less than 15% of tRA) or RXR␣ (less than 5% of 9-cis-RA) (Fig. 1a) . However, in the presence of RAR␥, activation was readily observed at 5 ϫ 10 Ϫ6 M, and at 10 Ϫ5 M, 4HPR showed more than 80% of the activity of tRA. Surprisingly, at 2 ϫ 10 Ϫ5 M 4HPR was even more potent than tRA (106%). In the presence of RAR␤, 4HPR also showed some activity but significant activation was seen only at 2 ϫ 10 Ϫ5 M, representing 48% of tRA activity. To ensure that the observed activities were not only specific for CV-1 cells, we also analyzed the activity of 4HPR in MCF-7 cells (Fig. 1b) . We again observed strong activation in the presence of RAR␥. At 10 Ϫ5 M, 4HPR showed approximately 60% of maximal tRA activity, while at 2 ϫ 10 Ϫ5 M activation by RAR␥ was even higher than that seen at an equivalent concentration of tRA. RAR␤ also induced strong activation of the reporter gene at 2 ϫ 10 Ϫ5 M, whereas little activation was observed in the presence of RAR␣ or RXR␣. 4MPR, an inert metabolite of 4HPR showed no activity in CV-1 and MCF-7 cells (Fig. 1a) . Thus at elevated concentrations, 4HPR, although it lacks a terminal carboxyl group, is a RAR␥/ ␤-selective transcriptional activator. inoid receptors bind to various DNA sequences, the RAREs, that can consist of variable arrangements of half-sites (hexameric sequences) (reviewed in Ref. 38) . These sequences are bound by RAR/RXR heterodimers and in some cases by RXR homodimers (6 -8) . We recently observed that activation of a particular heterodimer on various response elements can differ, such that it is in fact the retinoid receptor-DNA complex and not the receptors alone that determines the sensitivity to a retinoid ligand (36) . We investigated here whether the receptor activation selectivity of 4HPR could be further specified by different RAREs. The results are summarized in Table I . On the CRBPI-RARE, we found that 4HPR is a stronger activator than tRA and 9-cis-RA in the presence of RXR␥/RAR␥ (127%, 126%) and RXR␤/RAR␥ (125%, 117%) heterodimers (Table I) , while, in the case of the ApoA1 element, 4HPR was as potent as tRA and 9-cis-RA in the presence of RXR␤/RAR␥ (102%, 96%). Both of these RAREs are so-called DR-2s (direct repeat with a 2-base pair spacer). In contrast, 4HPR was a comparatively weak activator of the same receptor heterodimers on the ␤RARE (RXR␥/RAR␥: 45%, 19%), a DR-5 element (Table I) . As expected, 4HPR was also a poor activator of RAR␣ heterodimers, especially on the TREpal element (5 and 6% of 9-cis-RA and tRA, respectively, for RXR␣/RAR␣) and the ApoA1-RARE (13 and 7% of 9-cis-RA and tRA, respectively). Thus, 4HPR is a comparatively potent activator of RXR/RAR␥ combinations on certain response elements, such as the CRBPI, while it is a poor activator of the same receptors on the ␤RARE. It is therefore likely that 4HPR, in contrast to tRA or 9-cis-RA, activates only a selected set of retinoid-responsive genes, preferentially in cells expressing RAR␥ or ␤.
4HPR Transrepression Selectivity Is Distinct from Its Transactivation-An important activity of the retinoid receptors is their ability to inhibit the transcription factor AP-1 (39 -42), allowing for direct interference with cell proliferation signals (reviewed in Ref. 37 ). This transrepression is mechanistically distinct from transactivation (37, 41) . We analyzed the transrepression activity of 4HPR in HeLa cells using a collagenase promoter containing reporter construct (Col-CAT) as described previously (40, 41) . This promoter is induced by the tumor promoter TPA. 4HPR inhibited, in a concentration dependent manner, TPA-induced AP-1 activity in the presence of RARs and RXR␣, while transrepression in the absence of cotransfected receptors was not observed (Fig. 2) . Interestingly, a remarkable change in the order of effectivity was observed, in that RAR␥ in the presence of 4HPR was the weakest AP-1 inhibitor preceded by RXR␣, while RAR␤ and RAR␣ showed the strongest activity. 4MPR did not inhibit AP-1 activity with any of the receptors (data not shown). Thus, 4HPR is a potent AP-1 inhibitor, in particular in the presence of RAR␣ and ␤ where at 2 ϫ 10 Ϫ5 M it is as active as tRA. Interestingly, 4HPR also showed transrepression activity with RXR␣ which is not activated by tRA but requires 9-cis-RA for activation (40, 41) .
Antiproliferative Effects and Apoptosis Induction by 4HPR Correlate with Receptor Activation-If the antiproliferative activity reported for 4HPR is retinoid receptor-mediated, optimal
antiproliferative effects of 4HPR should be observed only at concentrations where optimal receptor activation is seen. We therefore analyzed the antiproliferative effects of 4HPR under our cell culturing conditions. We first studied the effect of 4HPR on three breast cancer cell lines and one cervical carcinoma cell line (HeLa) using tRA as a control. Cells were grown in the presence or absence of several retinoid concentrations for 96 h. At 2 ϫ 10 Ϫ5 M, 4HPR was a potent inhibitor of the growth of all four cell lines. Effects were clearly visible after 24 h, but the time frame of this cell killing varied somewhat in the four cell lines (Fig. 3) . At 10 Ϫ5 M, a strong growth inhibitory effect was still observed for the breast cancer cell lines, and this was more pronounced in the estrogen receptor-positive cell lines than in the estrogen receptor-negative cell lines (Hs578T). At 10 Ϫ6 and 5 ϫ 10 Ϫ6 M, the antiproliferative effect of 4HPR was clearly reduced. The HeLa cells used here showed less sensitivity to 4HPR in comparison to the estrogen receptor-positive breast cancer cells under study. These cells were also relatively insensitive to tRA (Fig. 3) . Overall, 4HPR was a much more potent cell growth inhibitor than tRA. Importantly, its activity on the cells increased dramatically between 10 Ϫ5 and 2 ϫ 10 Ϫ5 M, concentrations required for strong receptor transactivation and transrepression. We also analyzed 4HPR on two non-small cell lung cancer cell lines (Calu-6 and H661) as well as on an untransformed cell line (CV-1), using a colorimetric assay. Table II summarizes the data obtained with breast, lung, and cervical carcinoma cell lines and CV-1. These data reveal little cell-type specificity for 4HPR when used at 2 ϫ 10 Ϫ5 M, while at lower concentrations some cell-type selectivity was seen. Importantly, 4HPR showed a dramatic increase in antiproliferative/cytotoxic activity at concentrations at which it activated RAR␥ (10 Ϫ5 and 2 ϫ 10 Ϫ5 M). The metabolite 4MPR was inactive in the antiproliferation assay (Table II) .
From our analyses it became also apparent that 4HPR not only inhibited cell proliferation, but in fact reduced the cell numbers (Fig. 3) , consistent with previous observations demonstrating that 4HPR can induce apoptosis (26, 27, 34, 35) . We therefore also analyzed at what concentrations 4HPR could induce apoptosis in breast cancer cell lines. When T47D cells were grown for 24 h in various concentrations of 4HPR we observed a strong increase in apoptosis when 1 and 2 ϫ 10 Ϫ5 M of 4HPR were present, as determined by a cellular DNA fragmentation assay (Fig. 4 ). Thus at concentrations at which 4HPR is an effective activator of the retinoid receptors, it also induces apoptosis. 4MPR did not induce apoptosis (data not shown).
Effect of 4HPR on Receptor Expression-Expression of retinoid receptor mRNA levels can be regulated differentially in certain cell types by tRA. RAR␤2 expression is for instance up-regulated in many epithelial tissues in the presence of tRA and its basal expression is dependent on the vitamin A status of the animal (43) . In the lung as well as in breast cancer cell lines, RA up-regulates RAR␥ expression (43) (44) (45) . This ability of retinoids to induce the synthesis of their own receptors can in principle lead to a dramatic enhancement of the retinoid signal. We analyzed the effect of 4HPR on retinoid receptor mRNA levels in the MCF-7 breast cancer cell line and in CV-1 cells. These cell lines were found to express mostly RAR␣ and RAR␥ (44). When we compared RAR mRNA levels in the presence of 10 Ϫ5 M 4HPR we repeatedly observed increased RAR␥ mRNA expression in CV-1 and MCF-7 cells (1.4-and 1.8-fold) (Fig. 5) . Ϫ6 M as the highest concentration since no further substantial growth inhibition was seen when higher doses were used. Culture media and retinoids were replaced every 48 h. At the indicated time points, cells were detached with trypsin/EDTA, and the cell number was determined by counting. The values represent the average of at least three independent experiments. The variation coefficient was always below 10%. a The antiproliferative activity was determined using the colorimetric assay. A value of 100 represents the growth of cells in the absence of retinoids. tRA was analyzed at a maximum concentration of 10 Ϫ6 M since no substantial further growth inhibition was seen when higher doses of this retinoid were applied.
A similar moderate up-regulation of RAR␥ could be seen at 10 Ϫ6 M tRA, consistent with previous observations (44, 45) . In contrast, RAR␣ expression was not affected by the retinoids (Fig. 5) . RAR␤ expression was also not observed under these conditions (data not shown).
DISCUSSION
4HPR belongs to a special class of retinoids that can induce apoptosis in cancer cells as shown here and as reported previously (26, 27, 34) . Advances made in recent years in the deciphering of the molecular retinoid signaling pathways has revealed a complex network of receptor dimerizations and interactions with RAREs as well as other proteins, in particular the transcription factor AP-1. The natural retinoids tRA, and even more so 9-cis-RA, can elicit very broad and complex changes in gene expression. This is consistent with their broad biological activities. Synthetic retinoids can have limited activities and act only on selected receptors and response pathways therefore can be expected to induce different biological responses that may also be limited to certain cell types.
We show here that 4HPR can function as a selective retinoid that induces transcriptional activation preferentially by RAR␥ and to some extent by RAR␤ but not by RAR␣. Transactivation by RXR/RAR␥ heterodimers is further modulated by response elements. For instance, RAR␥ activation can be stronger than that seen in the presence of 9-cis-RA or tRA on certain response elements, while it is weaker on others. It has previously been shown that certain retinoids differ in their transactivation and transrepression activities (12) (13) (14) . Here we demonstrate that 4HPR is such a retinoid, since it shows anti-AP-1 activity (transrepression) mostly with RAR␣, RAR␤, and RXR␣. Thus, although 4HPR does not carry a terminal carboxyl group it activates certain nuclear retinoid receptors. Interaction of 4HPR with the receptors may be optimal under in vivo conditions when the receptor is already complexed with other receptors or proteins and/or DNA, consistent with our recent observation (36) that the ligand response of the retinoid receptors is modulated by the DNA elements they bind to. It is also conceivable that the 4HPR response of a retinoid receptor-DNA complex can be further influenced by the specific promoter contexts. Thus, our analysis leads us to propose that 4HPR is capable of inducing a very specific pattern of modulation of gene expression that can result in cellular responses very distinct from those observed in the presence of tRA and 9-cis-RA and which can include apoptosis.
The strong antiproliferative/apoptosis inducing activity we observed here, occurs at 4HPR concentrations where this retinoid shows optimal receptor activation capacity. It is therefore most likely that the biological response seen on cell cultures, in animals, and in patients are, or at least include, specific retinoid receptor mediated responses, resulting from retinoid receptor mediated changes in gene expression. The antiproliferative/apoptosis inducing activity we observed here at 10 Ϫ5 M and above is thus likely to be a specific receptor mediated response. At this point it cannot be excluded that the biological effects observed, including receptor activation, are caused by 4HPR metabolites other than 4MPR. Such unknown metabolites could be generated to various degrees in different cell types. Interestingly another synthetic retinoid that can induce apoptosis, CD437 (46) , 2 is also a selective activator of RAR␥ and, to a lesser extent, of RAR␤ (47) . Those findings would suggest that selective activation of RAR␥ could lead to activation of the apoptosis pathway. Increased RAR␥ expression induced by 4HPR could further enhance this mechanism. However, overexpression of certain RARs alone has also been reported to induce apoptosis (48) . In conclusion, 4HPR shows a selective retinoid receptor activation profile that could be the basis for its special biological activity. 
